CytoMed Historical Income Statement

GDTC Stock

2.96 0.47 13.70%

Historical analysis of CytoMed Therapeutics income statement accounts such as Research Development of 994 K or Total Operating Expenses of 3.8 M can show how well CytoMed Therapeutics Limited performed in making a profits. Evaluating CytoMed Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of CytoMed Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining CytoMed Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CytoMed Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About CytoMed Income Statement Analysis

CytoMed Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to CytoMed Therapeutics shareholders. The income statement also shows CytoMed investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

CytoMed Therapeutics Income Statement Chart

At present, CytoMed Therapeutics' Total Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Net Interest Income is expected to grow to about 283.1 K, whereas Depreciation And Amortization is forecasted to decline to about 66.2 K.

Research Development Total Operating Expenses Net Interest Income Selling General Administrative

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Most accounts from CytoMed Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into CytoMed Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2022	2023	2024	2025 (projected)
Other Operating Expenses	1.4M	3.2M	3.7M	3.9M
Depreciation And Amortization	291.8K	77.5K	69.7K	66.2K

Other Operating Expenses Depreciation And Amortization

CytoMed Therapeutics income statement Correlations

	Depreciation And Amortization	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Net Interest Income	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Net Income From Continuing Ops	Cost Of Revenue	Reconciled Depreciation	Income Tax Expense	Minority Interest
Depreciation And Amortization		-0.75	0.66	0.67	-0.38	0.71	-0.74	0.49	-0.46	0.48	-0.86	0.92	-0.12	-0.53	-0.41	-0.28	0.61	-0.83	-0.42	0.13	-0.47
Other Operating Expenses	-0.75		-0.97	-0.97	0.85	-0.98	1.0	-0.93	-0.21	-0.92	0.98	-0.85	0.72	0.91	0.84	0.78	-0.95	0.99	0.88	-0.68	0.9
Operating Income	0.66	-0.97		1.0	-0.9	1.0	-0.97	0.96	0.29	0.96	-0.94	0.82	-0.79	-0.89	-0.89	-0.83	0.96	-0.95	-0.9	0.76	-0.93
Ebit	0.67	-0.97	1.0		-0.9	1.0	-0.97	0.96	0.28	0.96	-0.94	0.83	-0.78	-0.89	-0.89	-0.83	0.96	-0.95	-0.89	0.76	-0.93
Research Development	-0.38	0.85	-0.9	-0.9		-0.88	0.86	-0.95	-0.58	-0.95	0.78	-0.66	0.86	0.9	0.98	0.96	-0.91	0.8	0.97	-0.77	0.94
Ebitda	0.71	-0.98	1.0	1.0	-0.88		-0.98	0.95	0.24	0.94	-0.96	0.85	-0.75	-0.88	-0.87	-0.81	0.96	-0.96	-0.88	0.73	-0.92
Total Operating Expenses	-0.74	1.0	-0.97	-0.97	0.86	-0.98		-0.93	-0.21	-0.93	0.98	-0.85	0.72	0.91	0.84	0.79	-0.95	0.99	0.88	-0.68	0.9
Income Before Tax	0.49	-0.93	0.96	0.96	-0.95	0.95	-0.93		0.52	1.0	-0.87	0.69	-0.85	-0.94	-0.93	-0.91	0.97	-0.88	-0.93	0.79	-0.92
Total Other Income Expense Net	-0.46	-0.21	0.29	0.28	-0.58	0.24	-0.21	0.52		0.54	-0.05	-0.18	-0.64	-0.46	-0.53	-0.64	0.38	-0.09	-0.52	0.54	-0.41
Net Income	0.48	-0.92	0.96	0.96	-0.95	0.94	-0.93	1.0	0.54		-0.86	0.67	-0.85	-0.94	-0.93	-0.92	0.97	-0.88	-0.93	0.79	-0.91
Net Interest Income	-0.86	0.98	-0.94	-0.94	0.78	-0.96	0.98	-0.87	-0.05	-0.86		-0.92	0.58	0.85	0.78	0.69	-0.91	1.0	0.8	-0.55	0.82
Interest Expense	0.92	-0.85	0.82	0.83	-0.66	0.85	-0.85	0.69	-0.18	0.67	-0.92		-0.34	-0.67	-0.65	-0.52	0.75	-0.9	-0.64	0.33	-0.69
Selling General Administrative	-0.12	0.72	-0.79	-0.78	0.86	-0.75	0.72	-0.85	-0.64	-0.85	0.58	-0.34		0.76	0.83	0.87	-0.77	0.61	0.89	-0.97	0.91
Selling And Marketing Expenses	-0.53	0.91	-0.89	-0.89	0.9	-0.88	0.91	-0.94	-0.46	-0.94	0.85	-0.67	0.76		0.93	0.93	-0.97	0.88	0.94	-0.63	0.84
Total Revenue	-0.41	0.84	-0.89	-0.89	0.98	-0.87	0.84	-0.93	-0.53	-0.93	0.78	-0.65	0.83	0.93		0.98	-0.93	0.8	0.98	-0.73	0.92
Gross Profit	-0.28	0.78	-0.83	-0.83	0.96	-0.81	0.79	-0.91	-0.64	-0.92	0.69	-0.52	0.87	0.93	0.98		-0.9	0.72	0.97	-0.75	0.89
Net Income From Continuing Ops	0.61	-0.95	0.96	0.96	-0.91	0.96	-0.95	0.97	0.38	0.97	-0.91	0.75	-0.77	-0.97	-0.93	-0.9		-0.93	-0.92	0.7	-0.88
Cost Of Revenue	-0.83	0.99	-0.95	-0.95	0.8	-0.96	0.99	-0.88	-0.09	-0.88	1.0	-0.9	0.61	0.88	0.8	0.72	-0.93		0.83	-0.58	0.84
Reconciled Depreciation	-0.42	0.88	-0.9	-0.89	0.97	-0.88	0.88	-0.93	-0.52	-0.93	0.8	-0.64	0.89	0.94	0.98	0.97	-0.92	0.83		-0.79	0.96
Income Tax Expense	0.13	-0.68	0.76	0.76	-0.77	0.73	-0.68	0.79	0.54	0.79	-0.55	0.33	-0.97	-0.63	-0.73	-0.75	0.7	-0.58	-0.79		-0.88
Minority Interest	-0.47	0.9	-0.93	-0.93	0.94	-0.92	0.9	-0.92	-0.41	-0.91	0.82	-0.69	0.91	0.84	0.92	0.89	-0.88	0.84	0.96	-0.88

Click cells to compare fundamentals

CytoMed Therapeutics Account Relationship Matchups

CytoMed Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	221.0K	243.9K	291.8K	77.5K	69.7K	66.2K
Other Operating Expenses	949.0K	1.3M	1.4M	3.2M	3.7M	3.9M
Operating Income	(949.0K)	(1.4M)	(1.4M)	(2.9M)	(2.6M)	(2.5M)
Ebit	(949.0K)	(1.4M)	(1.4M)	(3.0M)	(2.7M)	(2.6M)
Research Development	784.2K	806.4K	1.1M	1.2M	1.4M	994.0K
Ebitda	(728.0K)	(1.2M)	(1.1M)	(2.9M)	(2.6M)	(2.5M)
Total Operating Expenses	949.0K	1.3M	1.4M	3.1M	3.6M	3.8M
Income Before Tax	(1.5M)	(1.5M)	(2.3M)	(3.1M)	(2.8M)	(3.0M)
Total Other Income Expense Net	(513.2K)	(321.0K)	(922.5K)	(219.5K)	(197.6K)	(207.4K)
Net Income	(1.5M)	(1.5M)	(2.4M)	(3.1M)	(2.8M)	(3.0M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:

How To Invest In CytoMed

Details

Is CytoMed Stock a good investment?

Details

What is CytoMed Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.22)

Revenue Per Share

0.039

Quarterly Revenue Growth

(0.21)

Return On Assets

(0.17)

Return On Equity

(0.26)

The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CytoMed Historical Income Statement

About CytoMed Income Statement Analysis

CytoMed Therapeutics Income Statement Chart

Total Operating Expenses

Net Interest Income

CytoMed Therapeutics income statement Correlations

CytoMed Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CytoMed Therapeutics income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Cost Of Revenue	+ 1.0	Net Interest Income

Total Operating Expenses	- 0.98	Ebitda
Ebitda	- 0.98	Other Operating Expenses
Net Income From Continuing Ops	- 0.97	Selling And Marketing Expenses
Income Tax Expense	- 0.97	Selling General Administrative
Total Operating Expenses	- 0.97	Ebit
Total Operating Expenses	- 0.97	Operating Income